Background Age‐related macular degeneration (AMD) is the most common cause of
uncorrectable severe vision loss in people aged 55 years and older in the developed world …

Inhibition of angiogenesis is critical in the prevention and treatment of neovascular age-
related macular degeneration (AMD). Pathologic states such as hypoxia, ischemia, or …

PURPOSE: To evaluate the visual outcome, number of injections, and direct medical cost of
a “treat and extend” regimen (TER) in managing neovascular age-related macular …

PURPOSE: The vision gains reported with monthly intravitreal ranibizumab in the MARINA
and ANCHOR trials led to an immediate paradigm shift in the treatment of neovascular AMD …

Background: Intravitreal ranibizumab and pegaptanib are registered for neovascular age-
related macular degeneration. No formal safety study has been conducted for intravitreal …

PURPOSE: To investigate whether there is an association between complement factor H
(CFH) or LOC387715 genotypes with response to treatment with intravitreal bevacizumab …

PURPOSE: To report the frequency of optical coherence tomography (OCT) scan artifacts
and to compare macular thickness measurements, interscan reproducibility, and interdevice …

Purpose: To report the incidence of acute endophthalmitis as a complication of intravitreal
bevacizumab (Avastin)(IVB) injection in a tertiary vitreoretinal group practice. Methods: A …

PURPOSE: To describe the usage patterns of pharmacological treatments for neovascular
age-related macular degeneration (AMD) in Medicare fee-for-service beneficiaries. DESIGN …

The use of intravitreal bevacizumab (Avastin) has greatly expanded since its introduction
into ophthalmic care 3 years ago. A PubMed search on 1 August 2008 revealed 51 ocular …